OBJECTIVE: To determine whether there is an increased incidence of glucose intolerance in association with chronic terbutaline therapy, administered either orally or as a continuous subcutaneous infusion. METHODS: Sixty-nine women received terbutaline, orally (38 subjects) or as a continuous subcutaneous infusion (31 subjects). Their gestational diabetes screening results were compared to the results in 82 women not receiving beta-mimetic therapy. RESULTS: Subjects receiving terbutaline had significantly higher mean glucose concentrations after the 1-hour 50-g glucose tolerance test (GTT) than did controls (P < .05, one-way analysis of variance with multiple comparisons). Among subjects receiving a continuous subcutaneous infusion of terbutaline, the incidence of abnormal 3-hour 100-g GTT results was higher than among controls (20 versus 4%; P = .023 by chi 2). CONCLUSIONS: The incidence of GTT abnormalities is increased among women receiving terbutaline. We recommend surveillance of glucose tolerance among patients receiving terbutaline chronically, regardless of the route of administration.
OBJECTIVE: To determine whether there is an increased incidence of glucose intolerance in association with chronic terbutaline therapy, administered either orally or as a continuous subcutaneous infusion. METHODS: Sixty-nine women received terbutaline, orally (38 subjects) or as a continuous subcutaneous infusion (31 subjects). Their gestational diabetes screening results were compared to the results in 82 women not receiving beta-mimetic therapy. RESULTS: Subjects receiving terbutaline had significantly higher mean glucose concentrations after the 1-hour 50-g glucose tolerance test (GTT) than did controls (P < .05, one-way analysis of variance with multiple comparisons). Among subjects receiving a continuous subcutaneous infusion of terbutaline, the incidence of abnormal 3-hour 100-g GTT results was higher than among controls (20 versus 4%; P = .023 by chi 2). CONCLUSIONS: The incidence of GTT abnormalities is increased among women receiving terbutaline. We recommend surveillance of glucose tolerance among patients receiving terbutaline chronically, regardless of the route of administration.
Authors: Laura M Gaudet; Kavita Singh; Laura Weeks; Becky Skidmore; Alexander Tsertsvadze; Mohammed T Ansari Journal: PLoS One Date: 2012-02-21 Impact factor: 3.240